The MIT spinout that looked at the mRNA revolution, admired the message, and decided to rebuild the envelope.
In a lab off Kendall Square, the hard part of RNA medicine was never the RNA. It was getting it where it needed to go, intact, without setting the body on fire in the process. The world learned in 2021 that mRNA works. What fewer people learned is that the lipid nanoparticle carrying it - the tiny fatty bubble that made the vaccines possible - was also the thing limiting how much cargo you could send, how gently you could send it, and how warm you could keep it.
Tiba Biotech is the company that treated that limitation as the whole assignment. Instead of another lipid tweak, it built a fully synthetic, biodegradable dendrimer nanoparticle - a branching, tree-like molecule that grips RNA more firmly than small lipids do. The particles are roughly 100 to 150 nanometers across. They carry bigger, more complex payloads. They biodegrade. And they ask less of the cold chain.
The message was solved. Tiba is a company built to fix the delivery van.
It is a small operation - about nineteen people - with an unusually large map. Human vaccines. Cancer immunotherapy. Gene editing. And, uncommon for a Cambridge biotech, animal health, handled as the same engineering problem rather than a separate business.
Picture a molecular tree that branches over and over into a dense, symmetrical sphere. Those branch tips can be tuned to grab and protect RNA - which is exactly what Tiba does, swapping the fatty bubbles of first-generation mRNA for something engineered on purpose.
RNABL is the engine. Everything else is a place to drive it.
Synthetic biodegradable dendrimer nanoparticles that complex RNA, carry larger payloads than lipid nanoparticles, cut dose-limiting toxicity, and relax cold-chain demands.
Seasonal and pandemic influenza work, including the NIH CIVICs universal-flu program and a CEPI-funded “Disease X” readiness study.
Tissue-targeted delivery paired with enhanced self-amplifying RNA payloads, advanced under a National Cancer Institute SBIR award.
Using RNABL as the delivery layer for gene therapy and gene-editing payloads that strain conventional carriers.
RNA vaccines for animals, including a first livestock vaccine manufactured in Australia and a BARDA-backed influenza therapeutic.
Change how RNA travels and you change what RNA can do. Tiba treats the carrier, not just the code, as the invention.
The science was patented before the company existed. Filed at MIT in 2015; incorporated in 2018. What followed reads less like a startup arc and more like a string of government agencies deciding, one at a time, to place a bet.
MIT and the Whitehead Institute file a provisional patent for dendrimer nanoparticles.
A Zika virus vaccine candidate designed for the U.S. Army in a single week.
The company is formally established out of the university lab with seed capital.
U.S. Patent No. 10,548,959 is granted.
Joins the NIH CIVICs initiative pursuing a universal influenza vaccine.
A $2M partnership to benchmark RNABL against the field for pandemic readiness.
First livestock vaccine manufactured in New South Wales, Australia.
A $749,999 contract to develop RNA-based influenza therapeutics.
Most of Tiba's fuel is non-dilutive - grants and contracts from agencies whose job is to be ready before the next outbreak. When CEPI, BARDA, the NIH and the NCI all write checks to the same nineteen-person lab, the checks are the endorsement.
Approximate award sizes, by source.
Means “medicine” in Swahili and Arabic. The name is the mission statement.
The time it took to design a Zika vaccine candidate for the U.S. Army.
Its delivery particles are dendrimers - branching, tree-like molecules - not lipids.
The patent was filed three years before the company was incorporated.
Its first commercial-scale vaccine batch was made in rural New South Wales.
Human and animal disease, treated as one delivery problem under one roof.
Interviews and demos aren't always posted on a fixed page - these searches point to the latest from Tiba and its funders. Verify before you cite.
The hard part was never the RNA. It still isn't. Sit with the people at Tiba Biotech and the conversation keeps returning to the same unglamorous thing: how a molecule travels, how much it can carry, whether it survives the trip and the fridge.
That is the quiet wager here. Not a louder message - a better envelope. Bigger payloads. Less toxicity. A cold chain that forgives. And a platform aimed at flu, cancer, genetic disease and the diseases we haven't named yet, on the theory that if you fix the delivery van, you get to deliver a lot more than one thing.
The message was solved. Tiba Biotech is what happens when someone decides the delivery is the point.